^
Association details:
| Biomarker: | ER Y537S |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | amcenestrant (SAR439859) (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sar439859, a novel selective estrogen receptor degrader (serd), demonstrates effective and broad antitumor activity in wild-type and mutant er-positive breast cancer models
Published date:
11/17/2020
Excerpt:
...in vivo treatment with SAR439859 demonstrated significant tumor regression in ER+ breast cancer models including MCF7 ESR1 wild type and mutant-Y537S mouse tumors.
Source:
Title:
Pre-clinical development of next generation selective estrogen receptor degrader - SAR439859
Published date:
05/15/2020
Excerpt:
Here we describe the preclinical development of this molecule in multiple xenografts and demonstrated significant anti-tumor efficacy/regression in ER+ BC models including MCF7-ESR1 mutant-Y537S and endocrine therapy resistant patient-derived xenograft tumor models.
